These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26961773)

  • 1. Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases.
    Li Y; Pan W; Connolly ID; Reddy S; Nagpal S; Quake S; Gephart MH
    J Neurooncol; 2016 May; 128(1):93-100. PubMed ID: 26961773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.
    Momtaz P; Pentsova E; Abdel-Wahab O; Diamond E; Hyman D; Merghoub T; You D; Gasmi B; Viale A; Chapman PB
    Oncotarget; 2016 Dec; 7(51):85430-85436. PubMed ID: 27863426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain tumor mutations detected in cerebral spinal fluid.
    Pan W; Gu W; Nagpal S; Gephart MH; Quake SR
    Clin Chem; 2015 Mar; 61(3):514-22. PubMed ID: 25605683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid.
    White MD; Klein RH; Shaw B; Kim A; Subramanian M; Mora JL; Giobbie-Hurder A; Nagabhushan D; Jain A; Singh M; Kuter BM; Nayyar N; Bertalan MS; Stocking JH; Markson SC; Lastrapes M; Alvarez-Breckenridge C; Cahill DP; Gydush G; Rhoades J; Rotem D; Adalsteinsson VA; Mahar M; Kaplan A; Oh K; Sullivan RJ; Gerstner E; Carter SL; Brastianos PK
    JAMA Netw Open; 2021 Aug; 4(8):e2120040. PubMed ID: 34369989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease.
    Ballester LY; Glitza Oliva IC; Douse DY; Chen MM; Lan C; Haydu LE; Huse JT; Roy-Chowdhuri S; Luthra R; Wistuba II; Davies MA
    J Neuropathol Exp Neurol; 2018 Jul; 77(7):628-635. PubMed ID: 29873738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
    Gonzalez-Cao M; Mayo-de-Las-Casas C; Molina-Vila MA; De Mattos-Arruda L; Muñoz-Couselo E; Manzano JL; Cortes J; Berros JP; Drozdowskyj A; Sanmamed M; Gonzalez A; Alvarez C; Viteri S; Karachaliou N; Martin Algarra S; Bertran-Alamillo J; Jordana-Ariza N; Rosell R
    Melanoma Res; 2015 Dec; 25(6):486-95. PubMed ID: 26366702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF.
    Cheok SK; Narayan A; Arnal-Estape A; Gettinger S; Goldberg SB; Kluger HM; Nguyen D; Patel A; Chiang V
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma.
    Law V; Chen Z; Vena F; Smalley I; Macaulay R; Evernden BR; Tran N; Pina Y; Puskas J; Caceres G; Bayle S; Johnson J; Liu JKC; Etame A; Vogelbaum M; Rodriguez P; Duckett D; Czerniecki B; Chen A; Smalley KSM; Forsyth PA
    Neuro Oncol; 2022 Oct; 24(10):1673-1686. PubMed ID: 35213727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
    Santiago-Walker A; Gagnon R; Mazumdar J; Casey M; Long GV; Schadendorf D; Flaherty K; Kefford R; Hauschild A; Hwu P; Haney P; O'Hagan A; Carver J; Goodman V; Legos J; Martin AM
    Clin Cancer Res; 2016 Feb; 22(3):567-74. PubMed ID: 26446943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report.
    Kim DW; Barcena E; Mehta UN; Rohlfs ML; Kumar AJ; Penas-Prado M; Kim KB
    BMC Cancer; 2015 May; 15():400. PubMed ID: 25962795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
    Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U
    J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cerebral magnetic resonance imaging (MRI) in the diagnosis of leptomeningeal carcinomatosis in melanoma patients].
    Dupuis F; Sigal R; Margulis A; Mercier S; Spatz A; Mamelle G; Lartigau E; Duvillard P; Avril MF
    Ann Dermatol Venereol; 2000 Jan; 127(1):29-32. PubMed ID: 10717559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.
    Sakji-Dupré L; Le Rhun E; Templier C; Desmedt E; Blanchet B; Mortier L
    Melanoma Res; 2015 Aug; 25(4):302-5. PubMed ID: 25933211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
    Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
    Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.
    Li Y; Liu B; Connolly ID; Kakusa BW; Pan W; Nagpal S; Montgomery SB; Hayden Gephart M
    J Thorac Oncol; 2018 Jul; 13(7):1022-1027. PubMed ID: 29604399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
    Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
    Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
    Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
    Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient.
    Wu RC; Newman W; Patanowitz L; Branstetter BF; Amankulor N; Tarhini AA
    Immunotherapy; 2020 Aug; 12(11):763-769. PubMed ID: 32571131
    [No Abstract]   [Full Text] [Related]  

  • 20. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.